Testosterone replacement therapy in male hypogonadism

被引:11
作者
Byrne, MM [1 ]
Nieschlag, E [1 ]
机构
[1] Univ Munster, Inst Reprod Med, D-48129 Munster, Germany
关键词
testosterone; hypogonadism; transdermal testosterone; testosterone gel; dihydrotestosterone;
D O I
10.1007/BF03345206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In human males 6-7 mg of testosterone are secreted by the testes in a circadian rhythm with a nocturnal rise in testosterone followed by a decline during the day. Testosterone is necessary to induce and maintain secondary sexual characteristics, lean muscle mass, bone density and for normal sexual behaviour and cognitive function in men. Replacement therapy has been shown to be beneficial in men with overt hypogonadism. Natural testosterone should be used and not modified molecules. Testosterone is currently available in oral, intramuscular, subcutaneous and transdermal preparations. Recent advances in testosterone replacement therapy include testosterone gels which provide flexibility in dosing and minimal skin irritation resulting in good compliance, and the development of longer acting intramuscular preparations which result in more stable testosterone levels with longer injection intervals. All patients receiving testosterone should be carefully monitored for changes in hematocrit, liver function, lipid parameters and prostate specific antigen (PSA). This article reviews the current experience with the use of various forms of testosterone for the treatment of male hypogonadism. (C) 2003, Editrice Kurtis.
引用
收藏
页码:481 / 489
页数:9
相关论文
共 58 条
  • [1] 7α-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men
    Anderson, RA
    Martin, CW
    Kung, AWC
    Everington, D
    Pun, TC
    Tan, KCB
    Bancroft, J
    Sundaram, K
    Moo-Young, AJ
    Baird, DT
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (10) : 3556 - 3562
  • [2] [Anonymous], ANDROLOGY MALE REPRO
  • [3] Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system
    Arver, S
    Dobs, AS
    Meikle, AW
    Allen, RP
    Sanders, SW
    Mazer, NA
    [J]. JOURNAL OF UROLOGY, 1996, 155 (05) : 1604 - 1608
  • [4] Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men
    Arver, S
    Dobs, AS
    Meikle, AW
    Caramelli, KE
    Rajaram, L
    Sanders, SW
    Mazer, NA
    [J]. CLINICAL ENDOCRINOLOGY, 1997, 47 (06) : 727 - 737
  • [5] BALSPRATSCH M, 1986, LANCET, V2, P943
  • [6] Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
    Behre, HM
    Kliesch, S
    Leifke, E
    Link, TM
    Nieschlag, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (08) : 2386 - 2390
  • [7] BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341
  • [8] Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years
    Behre, HM
    von Eckardstein, S
    Kliesch, S
    Nieschlag, E
    [J]. CLINICAL ENDOCRINOLOGY, 1999, 50 (05) : 629 - 635
  • [9] TESTOSTERONE BUCICLATE (20 AET-1) IN HYPOGONADAL MEN - PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NEW LONG-ACTING ANDROGEN ESTER
    BEHRE, HM
    NIESCHLAG, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (05) : 1204 - 1210
  • [10] Behre HM, 1998, T-Action, deficiency, substitution, V21998, P329, DOI 10.1007/978-3-642-72185-4_11